A Prospective, Randomized, Vehicle-Controlled, Double-Blind, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of B244 Delivered as an Intranasal Spray for Preventive Treatment in Subjects With Episodic Migraine
Phase of Trial: Phase II
Latest Information Update: 21 Aug 2019
Price : $35 *
At a glance
- Drugs B 244 (Primary)
- Indications Migraine
- Focus Adverse reactions
- Sponsors AOBiome
- 19 Aug 2019 Status changed from active, no longer recruiting to completed.
- 14 Mar 2019 Planned End Date changed from 20 Feb 2019 to 20 Nov 2019.
- 14 Mar 2019 Planned primary completion date changed from 20 Feb 2019 to 20 Jul 2019.